What this is
A man whose sexual desire shuts down specifically with his committed partner, while desire for novelty and other women stays fully alive. Desire for her appears in novel contexts — travel, vacations, seeing her "fresh" — and rarely in daily domestic life. He rarely initiates; she does. The pattern repeats across relationships, over decades.
The mechanism — where every tradition converges
Five rival schools fight over the explanation, but the core observation is identical on every continent: familiarity re-files the partner out of the erotic category — into family, Madonna, friend, landscape, kin — and desire, which runs on otherness and novelty, cannot follow her there. In Berridge's neuroscience terms: it is a "wanting" failure with "liking" fully intact — which is why every arousal-side drug (erection, blood flow, bonding hormones) misses it completely.
Re-categorization
Freud's Madonna split, Japan's "she became family," China's 亲情化 (love converting to kinship), Korea's family catchphrase, Russia's "she's your friend now." The filing change is the event; everything else is commentary.
Habituation
Lab-documented since 1963: arousal habituates to a repeated stimulus and rebounds instantly to a novel one (the Coolidge effect). Crucially, labs also show dishabituation — after a novel interlude, the familiar stimulus regains response. Suppression behaves like a state, not a rewiring.
Difference
Clement (Germany) and Perel converge: desire develops out of difference — otherness, distance, not-knowing. Total domestic merger is structurally erotic-killing. The treatments that aim anywhere, aim here.
The honest verdicts
How to use this board
The Interventions tab rates everything anyone tries — drugs, psychedelics, therapies, body levers, practices, and things still in labs — on four scales. Bottom-rated items are included on purpose: tap them to see why they fail. The Men tab is the outcomes ledger: real first-person cases and what actually happened. The Stack is the assembled best-guess protocol, labelled as construction, not findings.
Everything, rated
Nothing excluded. Ratings are evidence-honest: a folk remedy with one small trial outranks a famous therapy with none.
Pattern fit — does it touch the partner-specific mechanism, or only general desire? Risk — side effects and dependence. Access — realistic availability from Colombia today.
Every culture names it
Eleven languages, five continents, one man. Tap a card for each culture's framing, its structural answer, and its honest verdict.
The men — what actually happened
First-person cases from the sweeps, with the long-term outcome where one exists. This is the only "outcome data" the world has published on this condition.
What's in the labs
The frontier sweep: drug pipelines, trial registries, psychedelic biotech, neurotech. Graded for stage and honesty — most of this is years away, and some of it is already dead.
Kisspeptin therapeutics
The most pattern-shaped molecule — quiets the brain's self-monitoring during desire (2023 JAMA randomized trial). Still two university groups, no company, and an unsolved delivery problem: continuous dosing stops working. Nasal-spray proof of concept exists (2025).
Oral MC4R agonists
Oral versions of bremelanotide's mechanism in development (Palatin PL7737; Dicot Pharma's LIB-01, Phase 2b planned 2026 — both aimed at ED/obesity first). An oral "wanting" pill is a plausible derivative, not an announced product.
MDMA regulatory decision
Resubmitted to the FDA in Aug 2026 without the extra Phase 3 the agency demanded; advocate forecast of a decision ~Q1 2027 (speculation). Even a yes covers PTSD only — but it opens the door for couples-format research. The VA couples pilot showed big relationship-satisfaction gains, partial fade at follow-up, zero desire endpoints.
VR inoculation
Birnbaum's lab experiments (Reichman University): flirting with a virtual bartender increased desire for the real partner and decreased desire for alternatives. The only experimental paradigm ever to move partner-specific desire in the right direction. No product, no trial — a paradigm in search of a builder.
GLP-1 drugs — the accidental experiment
Millions now take broad "wanting" modulators. Data are mixed and individual: some report blunted novelty-seeking and compulsivity; desire effects inconsistent. Plausible direction for this pattern: dulling the novelty pull, not restoring partner desire. Nobody is trialing it for either. Watch, don't pursue.
AI intimacy concierges
Arya (~$37M raised) and rivals are productizing self-expansion — curated novelty delivered to couples by app. The distribution vehicle for "engineered novelty" exists years before any outcome data does. Funded, marketed, unmeasured.
Neurostimulation — dead end
One TMS finding from 2016 (reward anticipation shifted by DLPFC stimulation), no follow-up program; tDCS replication null; no neurofeedback work on habituation exists. This frontier stalled a decade ago.
The cut assets
Initiator Pharma discontinued IP2018 — the one pipeline drug aimed at psychogenic desire problems — in April 2026. Flibanserin-in-men is dead. The desire-drug industry is developing almost entirely around women; male partner-specific desire has no commercial champion.
The Stack — assembled, not found
No source anywhere proposes a complete protocol. This stack is my construction from the pieces the sweeps graded highest — each piece real, the combination untested. Read it as engineering, not medicine.
1Volume — episodic wanting-amplification
An on-demand MC4R-class agent (bremelanotide exists now; oral successors in development) used episodically rather than daily — raising general desire at chosen moments instead of waiting for spontaneous desire that the wiring won't supply at home. General, not targeted — which is why it needs layer 2.
2Aim — engineered novelty as recurring infrastructure
The self-expansion dose, scheduled like training: novel shared contexts on a cadence (the Muise data; every culture's vacation effect). Novelty behaves like a recurring dose, not a vaccine — so it gets calendared, not hoped for. The lab's dishabituation and VR-inoculation findings say the familiar stimulus can re-light when novelty is dosed deliberately.
3Perception — attention retraining
Sexual mindfulness: the one tantra component with correlational support, and the active ingredient inside sensate focus. Slow, sensation-first, non-goal encounters that retrain perception of the familiar partner — plus the responsive-desire reframe: desire is allowed to follow starting; it is not required to precede it.
4Distance — structural otherness
Clement's layer: separate pursuits, time apart, her seen in social/novel frames — the contexts where the desire already fires. Korea's version: drop the parent masks at the bedroom door. Distance is dosed on purpose, not left to chance travel.
5Reset — periodic psychedelic sessions, if the door opens
Psilocybin is the only substance class with partner-attraction gains in two independent datasets; MDMA couples work shows closeness gains (with fade). Occasional, guided, together — a periodic reset of perception, not a daily drug. Regulatory status varies; the MDMA decision (~2027) is the bellwether.
6Base — sleep
The one degraded background system with hard data behind it: a week of 5-hour nights cuts testosterone 10–15%; sleep disorders roughly double sexual-dysfunction risk. Unsexy, real, and upstream of everything above.